Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides

Antonio Di Biagio,Niccolò Riccardi,Lucia Taramasso,Amedeo Capetti,Giovanni Cenderello,Alessio Signori,Paola Vitiello,Michele Guerra,Giuseppe Vittorio de Socio,Giovanni Cassola, Tiziano Quirino,Claudio Viscoli

International Journal of Antimicrobial Agents（2016）

引用 9|浏览17

暂无评分

摘要

•Switch from unboosted protease inhibitor to an RPV/FTC/TDF-based single-tablet regimen among HIV-1-infected patients is proposed.•The switch is safe and associated with a reduction in plasma triglycerides and plasma cholesterol.•Decrease in cART-related costs and non-cART patient management is highlighted.

查看译文

关键词

Rilpivirine,Switch,Unboosted protease inhibitor,Ritonavir-sparing,Cholesterol,Triglycerides

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要